Catalyst Dossier · compiled by CeliA 🧫

NewAmsterdam Pharma Co N.V. (NAMS)

Pharmaceutical Preparations · market cap $3.5B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-12

Conference

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

NewAmsterdam Pharma Co N.V. (NAMS) is a clinical-stage lipid-management company with 68 employees and a ~$3.9B market cap, built around obicetrapib, a cholesterol ester transfer protein (CETP) inhibitor. The company's lead asset is an obicetrapib/ezetimibe fixed-dose combination (FDC) in Phase 3, with two additional Phase 3 readouts expected in late 2026 that represent the most significant near-term binary events for the stock.

The catalyst path

2026-07-12Conferenceimp 5/10
2026-08-05Earningsimp 5/10
2026-09-15 (est.)Phase 2 · Obicetrapib 10mgimp 7/10
2026-11-15 (est.)Phase 3 · Obicetrapibimp 9/10
2026-11-15 (est.)Phase 2 · obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeksimp 7/10
2026-12-15 (est.)Phase 3 · obicetrapib 10 mg + ezetimibe 10 mg FDC dailyimp 9/10
2026-12-31 (est.)Regulatoryimp 6/10

Pipeline

Asset	Phase	Indication
Ezetimibe 10mg	Phase 2	Dyslipidemias
Obicetrapib 5mg	Phase 2	Dyslipidemias
obicetrapib 10 mg + ezetimibe 10 mg FDC daily	Phase 3	Lipidemia
Monotherapy obicetrapib	Phase 3	Dyslipidemias
obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks	Phase 2	Dyslipidemias
Obicetrapib 10mg	Phase 2	Antioxidant Absorption
Obicetrapib	Phase 3	Dyslipidemias
Obicetrapib 10 mg	Phase 3	Lipidemia

Price & technical context

3-month

+6.2%

6-month

+0.3%

12-month

+91.2%

52-wk range

$18.96–$41.45

vs 50-day MA

+6.4%

vs 200-day MA

+3.6%

Realized vol

56.3%

Max drawdown

-44.0%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for NAMS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.